Quick Answer
Evofem Biosciences, Inc. reported Diluted EPS of $0.12 per share (loss) for fiscal year 2024.
Evofem Biosciences, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2024 | -$0.12 | -340.0% |
| 2023 | $0.05 | +100.0% |
| 2022 | -$167.42 | -608.5% |
| 2021 | -$23.63 | -1014.6% |
| 2020 | -$2.12 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.01 | +50.0% | +50.0% |
| June 30, 2025 | -$0.02 | — | — |
| March 31, 2025 | $0.00 | +100.0% | +100.0% |
| September 30, 2024 | -$0.02 | -120.0% | — |
| June 30, 2024 | $0.00 | +100.0% | +100.0% |
| March 31, 2024 | -$0.16 | +91.4% | -260.0% |
| September 30, 2023 | $0.10 | +102.3% | +101.8% |
| June 30, 2023 | -$5.43 | +99.1% | -193.5% |
- Evofem Biosciences, Inc. showed a decrease of -340.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2024 period, Evofem Biosciences, Inc.’s diluted eps has grown by 94.3% (from $2.12 per share (loss) to $0.12 per share (loss)).
- The most recent figure is from Evofem Biosciences, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 24, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: